Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 6, 2006, Pages 735-741

  Iwasaki, Yoshinobu ^a   Ohsugi, Shuji ^a   Natsuhara, Atsushi ^a   Tsubokura, Takuji ^a   Harada, Hidehiko ^b   Ueda, Mikio ^c   Arimoto, Taichiro ^a   Hara, Hiroshi ^b   Yamada, Tadaaki ^a   Takesako, Toshiyuki ^a   Kohno, Kenji ^a   Hosogi, Shigekuni ^a   Nakanishi, Masaki ^a   Marunaka, Yoshinori ^a   Nishimura, Tsunehiko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ESOPHAGITIS; ESOPHAGUS DISEASE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33748472091     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0220-y     Document Type: Article

References (28)

1. Dillman RP, Herndon J, Seagren SL, Eaton Jr WL, Green MR (1966) Improved survival in stage III NSCLC: seven year follow-up of CALGB 8433. J Natl Cancer Inst 88:1210
2. LeChevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier M, Douillard J, Laplanche (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial of 353 patients. J Natl Caner Inst 83:417
3. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899
4. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692
5. Curran W, Scott C, Langer R, Komaki R, Lee J, Hauser S, Movsas B, Wasserman T, Russell A, Byhardt R, Sause W, Cox J (2000) Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 29:93 (abstr 303)
6. Milas L, Milas MM, Mason KA (1999) Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 9(suppl 1):12
7. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1996) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 56:1842
8. Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, Milas L (1999) Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 5:4191
9. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18:599
10. Wu H, Bang Y, Choi EK, Ahn YC, Kim YW, Lim TH, Suh C, Park K, Park CI (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage IIII no-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:75
11. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa M, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S et al (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Brit J Cancer 89:795
12. Isla D, Rosell R, Sanchez JJ, Carrato A, Felip E, Camps C, Artal A, Gonzalez-Larriba JL, Azagra P, Alberola V, Martin C, Massuti B (2001) Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 19:1071
13. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 16:3316
14. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 23:5883
15. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Wilder R, Ryu J, Doroshow J (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California cancer consortium phase II trial. J Clin Oncol 19:442
16. Vokes EE, Herndon JE, Kelley MJ, Watson D, Cicchetti G, Green MR (2004) Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 22:148 (abstr 7005)
17. Zeinner R, Fossella F, Komaki R, Delclos M, Jung M, Glisson BS, Lee JS, Pisters K, Jhingran A, Hong WK (1999) Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus cisplatin (CDDP), for patients with stage III and medically inoperable stage II non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18:466a (abstr 1798)
18. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191
19. Vokes EE, Herndon JE, Kelley MJ, Watson D, Cicchetti MG, Green MR (2004) Cancer and Leukemia Group B. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 22:14S (abstr 7005)
20. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004
21. Kelly K, Gaspar LE, Chansky K, Albain KS, Crowley J, Gandara DR, Southwest Oncology Group (2005) Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 23:634S (abstr 7058)
22. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R et al (1994) Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238
23. Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Woolley KJ, Heelan RT (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232
24. 2 dose of docetaxel and prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968
25. Harper P (1997) The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer. Semin Oncol 24:S30
26. Schiller JH (1998) Role of taxanes in lung-cancer chemotherapy. Cancer Invest 16:471
27. Eisenhauer EA (1995) Docetaxel: current status and future prospects. J Clin Oncol 13:2865
28. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt PA, Slovis B, Laporte K, Shyr Y, Johnson DH (2001) Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) trial. Lung Cancer 34:441